2002
DOI: 10.1182/blood.v99.2.724
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus–infected patients treated for non-Hodgkin lymphoma

Abstract: equivalent treatments. With only 90 participants, the study has insufficient power to permit any valid statement on the equivalence of the treatments, a weakness acknowledged by the authors in the final sentence of their manuscript. 2 Equivalency studies must be designed in accordance with strict methodologic criteria in order for their conclusions to have any statistical validity. 3 The unambiguous outcome of the Barritt and Jordan study and the totality of subsequent medical literature and clinical experienc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
36
0
3

Year Published

2003
2003
2008
2008

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 67 publications
(39 citation statements)
references
References 12 publications
0
36
0
3
Order By: Relevance
“…Prophylactic treatment with antiviral nucleotide analogue lamivudine prior to the start of chemotherapy has been suggested to be effective in reducing the incidence of HBV reactivation (Rossi et al, 2001;Liao et al, 2002;Lim et al, 2002;Persico et al, 2002;Shibolet et al, 2002;Yeo et al, 2002). The use of the proposed predictive model may aid the identification of high-risk patients who stand to benefit most from the antiviral, which could in turn be administered in a most cost-effective manner.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Prophylactic treatment with antiviral nucleotide analogue lamivudine prior to the start of chemotherapy has been suggested to be effective in reducing the incidence of HBV reactivation (Rossi et al, 2001;Liao et al, 2002;Lim et al, 2002;Persico et al, 2002;Shibolet et al, 2002;Yeo et al, 2002). The use of the proposed predictive model may aid the identification of high-risk patients who stand to benefit most from the antiviral, which could in turn be administered in a most cost-effective manner.…”
Section: Discussionmentioning
confidence: 99%
“…The incidence of HBV reactivation in hepatitis B surface antigen (HBsAg) seropositive cancer patients undergoing cytotoxic chemotherapy has been reported to be 20% or higher (Lok et al, 1991;Nokamura et al, 1996;Kumagai et al, 1997;Markovic et al, 1999;Yeo et al, 2000a). No preventive measures have been proven to prevent or reduce the incidence of HBV reactivation, although more recent reports have suggested that the prophylactic use of the antiviral agent lamivudine, prior to the start of chemotherapy, may reduce the occurrence of the condition (Rossi et al, 2001;Liao et al, 2002;Lim et al, 2002;Persico et al, 2002;Shibolet et al, 2002;Yeo et al, 2002). There has also been concern about the emergence of viral mutant as a result of lamivudine therapy, and, to date, limited data are available on the clinical impact of these mutants in immunosuppressed subjects.…”
mentioning
confidence: 99%
“…This will lead to the development of lamivudine resistance caused by point mutations, with substitution of either valine or isoleucine for the amino acid position 204 methionine (rtM204V or rtM204I, respectively) in the HBV DNA polymerase gene (tyrosinemethionine-aspartate-aspartate [YMDD] motif) [67]. Its risk increases as the therapy is prolonged, reaching a level of 67% after 4 years in nonimmunocompromised patients Jang et al 88 Lim et al 127 Yeo et al 119 Lee et al 118 Idilman et al 117 Yeo et al 116 Leaw et al 115 Ozguroglu et al 114 Lau et al 85 Persico et al 113 Shibolet et al 112 Dai et al 111 Nagamatue et al 58 0.001 0.01 0.1 1 10 100 1000…”
Section: Preemptive Use Of Nucleoside Analoguesmentioning
confidence: 99%
“…On the other hand, prolonged therapy with nucleos(t)ide analogues is associated with an increased likelihood of developing lamivudine-resistant mutants. Hence, most cancer centers would aim at discontinuing or withdrawing preemptive lamivudine as soon as possible to limit the duration of antiviral therapy [57,85,86,[111][112][113][114][115][116][117][118][119]127]. However, at the moment there is no available consensus on the optimal duration of lamivudine therapy.…”
Section: Preemptive Use Of Nucleoside Analoguesmentioning
confidence: 99%
“…[1][2][3] These reactivations have been observed, especially in hepatitis B surface antigen (HBsAg)-positive subjects 4 and they occur in 20%-50% of cases, with a mortality rate of 10%-40%. Consequently, lamivudine prophylaxis is strongly recommended in HBsAg-positive subjects receiving chemotherapy or immunosuppressive therapy, [5][6][7] although there are no clear guidelines for HBsAg-negative subjects.…”
Section: Introductionmentioning
confidence: 99%